Dr. Reddys Laboratories Ltd 2014 AR2
The report highlights Dr. Reddy's Laboratories Limited's financial and operational performance for the fiscal year 2013-14. The company achieved a consolidated revenue of ‹132.2 billion, representing a 13.7% year-on-year growth, driven primarily by its Global Generics segment in North America and emerging markets. Key achievements include the launch of nine new products in North America, such as complex injectables decitabine and azacitidine, and the introduction of product innovations like Metsmall and Optidoz in India. Additionally, the company invested 9.4% of its sales in research and development and expanded its manufacturing capabilities with new automated facilities.
Company: Dr. Reddys Laboratories Ltd
Sector: Health Care
Country: India
Year: 2014
Type: AR2
Pages: 228
Back to company
Dr. Reddys Laboratories Ltd
Annual Report
The report highlights Dr. Reddy's Laboratories Limited's financial and operational performance for the fiscal year 2013-14. The company achieved a consolidated revenue of ‹132.2 billion, representing a 13.7% year-on-year growth, driven primarily by its Global Generics segment in North America and emerging markets. Key achievements include the launch of nine new products in North America, such as complex injectables decitabine and azacitidine, and the introduction of product innovations like Metsmall and Optidoz in India. Additionally, the company invested 9.4% of its sales in research and development and expanded its manufacturing capabilities with new automated facilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2014
Reporting Period
Apr 1, 2013 - Mar 31, 2014
Fiscal Year
2014
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Renewable Energy
Employees